학술논문

Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study

Document Type

Article

Author

Reinmuth, N.; Cho, B.C.; Lee, K.H.; Luft, A.; Ahn, M.-J.; Schneider, J.; Shepherd, F.A.; Geater, S.L.; Pápai-Székely, Z.; Van Ngoc, T.; Garassino, M.C.; Liu, F.; Clemett, D.; Thiyagarajah, P.; Scheuring, U.; Ouwens, M.; Peters, S.; Rizvi, N.

Source

In: Annals of oncology : official journal of the European Society for Medical Oncology. (Annals of oncology : official journal of the European Society for Medical Oncology, 1 April 2019, 30:ii77)

Subject

Language

English

ISSN

15698041

Online Access

Full Text (ScienceDirect 종량제) Full Text (ScienceDirect O/A) Open Access (EBSCO) Web of Science JCR 저널정보 Scopus Find it@PNU

이메일

부산대학교 도서관

Online Access

메일 발송